Jordi Bonaventura

Jordi Bonaventura

Auto-generated profile, based on publicly available information

Jordi Bonaventura

Universitat de Barcelona

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2017 in Science
Verified
Journal Article
Closed access
PDF file
JGJuan L. Gomez
Juan L. Gomez
JBJordi Bonaventura
Jordi Bonaventura
WLWojciech Lesniak
Wojciech Lesniak
WMWilliam B. Mathews
William B. Mathews
PSPolina Sysa-Shah
Polina Sysa-Shah
MMMichael Michaelides
Michael Michaelides
DREADD not the designer compound: Designer receptors exclusively activated by designer drugs (DREADDs) constitute a powerful chemogenetic strategy that can modulate nerve cell activity in freely moving animal preparations. Gomez et al. used radioligand receptor occupancy measurements and in vivo positron emission tomography to show that DREADDs expressed in the brain are not activated by the designer compound CNO (clozapine N -oxide). Instead, they are activated by the CNO metabolite clozapine, a drug with multiple endogenous targets. This may have important implications for the interpretation of results obtained with this popular technology. Science , this issue p. 503

15 April 2021 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
JBJordi Bonaventura
Jordi Bonaventura
SLSherry Lam
Sherry Lam
MCMeghan Carlton
Meghan Carlton
MBMatthew A. Boehm
Matthew A. Boehm
JGJuan L. Gomez
Juan L. Gomez
MMMichael Michaelides
Michael Michaelides

11 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJordi Bonaventura
Jordi Bonaventura
MEMark Eldridge
Mark Eldridge
FHFeng Hu
Feng Hu
JGJuan L. Gomez
Juan L. Gomez
MSMarta Sanchez-Soto
Marta Sanchez-Soto
MMMichael Michaelides
Michael Michaelides
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a popular chemogenetic technology for manipulation of neuronal activity in uninstrumented awake animals with potential for human applications as well. The prototypical DREADD agonist clozapine N-oxide (CNO) lacks brain entry and converts to clozapine, making it difficult to apply in basic and translational applications. Here we report the development of two novel DREADD agonists, JHU37152 and JHU37160, and the first dedicated 18F positron emission tomography (PET) DREADD radiotracer, [18F]JHU37107. We show that JHU37152 and JHU37160 exhibit high in vivo DREADD potency. [18F]JHU37107 combined with PET allows for DREADD detection in locally-targeted neurons, and at their long-range projections, enabling noninvasive and longitudinal neuronal projection mapping.

14 March 2019 in Science
Verified
Journal Article
Closed access
CMChristopher J. Magnus
Christopher J. Magnus
PLPeter H. Lee
Peter H. Lee
JBJordi Bonaventura
Jordi Bonaventura
RZRoland Zemla
Roland Zemla
JGJuan L. Gomez
Juan L. Gomez
SSScott M. Sternson
Scott M. Sternson
Improved agonists for chemogenetics: Targeting ligand-responsive receptors to specific groups of cells, a strategy known as chemogenetics, is a powerful tool in many neurological applications. There is increasing interest in extending these tools for human treatment. Magnus et al. designed chemogenetic ion channels that improve currently available systems and are activated by the clinically used antismoking drug varenicline. They engineered a ligand-binding domain less responsive to endogenous signals and identified agonists that function at nanomolar concentrations. The combination of drug and introduced channels transiently silenced neurons, with slow but effective washout, and induced behavioral changes in animal models after brain administration. Science , this issue p. eaav5282

22 June 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JBJordi Bonaventura
Jordi Bonaventura
GNGemma Navarro
Gemma Navarro
VCVerònica Casadó-Anguera
Verònica Casadó-Anguera
KAKarima Azdad
Karima Azdad
WRWilliam Rea
William Rea
VCVicent Casadó
Vicent Casadó
Significance: G protein-coupled receptors (GPCRs) constitute the largest plasma membrane protein family involved in cell signaling. GPCR homodimers are predominant species, and GPCR heteromers likely are constituted by heteromers of homodimers. The adenosine A 2A receptor (A 2A R)-dopamine D 2 receptor (D 2 R) heteromer is a target for the nonselective adenosine receptor antagonist caffeine. This study uncovers allosteric modulations of A 2A R antagonists that mimic those of A 2A R agonists, challenging the traditional view of antagonists as inactive ligands. These allosteric modulations disappear when agonist and antagonist are coadministered, however. A model is proposed that considers A 2A R-D 2 R heteromers as heterotetramers, constituted by A 2A R and D 2 R homodimers. The model predicted that high concentrations of A 2A R antagonists would behave as A 2A R agonists and decrease D 2 R function in the brain.

18 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GNGemma Navarro
Gemma Navarro
EMEstefanía Moreno
Estefanía Moreno
JBJordi Bonaventura
Jordi Bonaventura
MBMarc Brugarolas
Marc Brugarolas
DFDaniel Farré
Daniel Farré
PMPeter J McCormick
Peter J McCormick
Under normal conditions the brain maintains a delicate balance between inputs of reward seeking controlled by neurons containing the D1-like family of dopamine receptors and inputs of aversion coming from neurons containing the D2-like family of dopamine receptors. Cocaine is able to subvert these balanced inputs by altering the cell signaling of these two pathways such that D1 reward seeking pathway dominates. Here, we provide an explanation at the cellular and biochemical level how cocaine may achieve this. Exploring the effect of cocaine on dopamine D2 receptors function, we present evidence of σ1 receptor molecular and functional interaction with dopamine D2 receptors. Using biophysical, biochemical, and cell biology approaches, we discovered that D2 receptors (the long isoform of the D2 receptor) can complex with σ1 receptors, a result that is specific to D2 receptors, as D3 and D4 receptors did not form heteromers. We demonstrate that the σ1-D2 receptor heteromers consist of higher order oligomers, are found in mouse striatum and that cocaine, by binding to σ1 -D2 receptor heteromers, inhibits downstream signaling in both cultured cells and in mouse striatum. In contrast, in striatum from σ1 knockout animals these complexes are not found and this inhibition is not seen. Taken together, these data illuminate the mechanism by which the initial exposure to cocaine can inhibit signaling via D2 receptor containing neurons, destabilizing the delicate signaling balance influencing drug seeking that emanates from the D1 and D2 receptor containing neurons in the brain.